Sartorius reported its Q1 17 results slightly ahead of the Street’s expectations, driven by a combination of strong organic growth and higher than expected M&A contribution in the Lab Products division (IntelliCyt, ViroCyt and Essen Bioscience). Net sales increased 13.6% yoy (12.2% in cc) to €343.1m (vs. our expectation of c.€337m) while adjusted EBITDA margin rose 70bp to 24.7%. At the segmental level, strong double-digit growth in the Lab Product segment (21% cc growth,
29 Jun 2017
M&A gains drive outperformance but limited triggers ahead
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
M&A gains drive outperformance but limited triggers ahead
Sartorius AG (0NIQ:LON) | 13,825 0 0.0% | Mkt Cap: 10,352m
- Published:
29 Jun 2017 -
Author:
Jyoti Prakash -
Pages:
4
Sartorius reported its Q1 17 results slightly ahead of the Street’s expectations, driven by a combination of strong organic growth and higher than expected M&A contribution in the Lab Products division (IntelliCyt, ViroCyt and Essen Bioscience). Net sales increased 13.6% yoy (12.2% in cc) to €343.1m (vs. our expectation of c.€337m) while adjusted EBITDA margin rose 70bp to 24.7%. At the segmental level, strong double-digit growth in the Lab Product segment (21% cc growth,